Pharmacy Compounding Safety Precautions

Which route of administration is suitable for an unconscious patient?

Which route of administration is generally effective unless rapidly deactivated by liver metabolism?

Which route of administration is ideal for systemic absorption due to high blood flow and increased rate of absorption?

Which route of administration involves application to the skin surface for slow absorption into systemic circulation?

Which type of drugs are suitable for rectal/vaginal administration?

Which route of administration bypasses biological membranes leading to rapid distribution?

For which type of drugs is inhalation administration particularly suitable?

Which route of administration is good for self-administration and has a high rate of absorption due to increased blood flow?

Which route of administration is absorbed mostly systemically but can have some hepatic portal circulation occur?

Which route of administration is suitable when distribution needs to be rapid by bypassing biological membranes?

Compounding can be carried out by any pharmacy staff member, not necessarily a trained pharmacist.

If a pharmacist is asked to compound a medicine previously compounded by another pharmacist, they do not need to ensure consistency in the compounding process.

Compounding without considering clinical and pharmaceutical knowledge is acceptable when there are no precedents.

Compounded medicines should always be provided, regardless of the availability of commercial products.

Pharmacists are not allowed to compound medicines for human patients, only for animals.

If a compounded medicine is similar to a commercially available product and will produce the same therapeutic outcome, it should still be compounded.

Complex compounding involves the preparation and supply of multiple units of a therapeutic product intended for supply to multiple patients.

Compounding facilities may require specific equipment like a pressurized clean room with a laminar flow cabinet for certain types of compounding.

Micro-dose single unit dosage forms should contain more than 50mg of active ingredient to be considered suitable for compounding.

Sustained release or modified release preparations are examples of compounding that do not require any specific competencies or equipment.